Contrasting Portage Biotech (NASDAQ:ATON) & Acerus Pharmaceuticals (OTCMKTS:TRLPF)

Portage Biotech (NASDAQ:ATON) and Acerus Pharmaceuticals (OTCMKTS:TRLPF) are both small-cap manufacturing companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.

Profitability

This table compares Portage Biotech and Acerus Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Portage Biotech	N/A	N/A	N/A
Acerus Pharmaceuticals	-254.66%	-346.72%	-94.54%

Insider and Institutional Ownership

13.4% of Portage Biotech shares are held by institutional investors. Comparatively, 0.0% of Acerus Pharmaceuticals shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Portage Biotech has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. Comparatively, Acerus Pharmaceuticals has a beta of 2.6, indicating that its stock price is 160% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Portage Biotech and Acerus Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Portage Biotech	1	0	1	0	2.00
Acerus Pharmaceuticals	0	0	0	0	0.00

Portage Biotech currently has a consensus target price of $2.00, suggesting a potential upside of 502.41%. Given Portage Biotech’s stronger consensus rating and higher possible upside, equities analysts plainly believe Portage Biotech is more favorable than Acerus Pharmaceuticals.

Valuation & Earnings

This table compares Portage Biotech and Acerus Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Portage Biotech	N/A	N/A	-$6.77 million	($8.18)	-0.04
Acerus Pharmaceuticals	$7.38 million	7.71	-$18.79 million	($0.08)	-2.75

Portage Biotech has higher earnings, but lower revenue than Acerus Pharmaceuticals. Acerus Pharmaceuticals is trading at a lower price-to-earnings ratio than Portage Biotech, indicating that it is currently the more affordable of the two stocks.

Summary

Portage Biotech beats Acerus Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

About Portage Biotech

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company’s product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.

About Acerus Pharmaceuticals

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.